uniQure ($QURE) disclosed FDA feedback stating Phase I/II data for its Huntington's gene therapy AMT-130—delivered via ClearPoint Neuro's platform—was insufficient without a prospective, randomized, sham-controlled Phase 3 trial. Released early March 2, this news fueled fears over regulatory hurdles for CLPT-enabled brain delivery programs, amplifying negative sentiment amid recent declines (e.g., -12.89% prior session). Premarket volume reflected algo and retail selling, extending multi-day weakness ahead of Q4 earnings on March 4. Posts from financial commentators highlighted the partnership risk.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.